A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer

Neoadjuvant or adjuvant therapy for resectable gastric cancer: a systematic review and practice guideline for North America

“…One Phase III RCT comparing postoperative CRT versus postoperative chemotherapy was identified [28]. Initially, the chemotherapy regimen consisted of docetaxel and cisplatin.…”

Phase I study of docetaxel, cisplatin and concurrent radiotherapy for locally advanced gastric adenocarcinoma

“…With this technique, the total dose is slightly improved to 50.4Gy which is employed in other reports [10,21]. This dose is slightly higher as compared with 40 to 45 Gy in other Phase II-III studies in adjuvant or definitive settings [22,23]. Its goal is to improve the local controlling as well as optimize systemic therapy without increase of dose-limiting radiotherapy toxicities.…”

Postoperative chemotherapy in gastric cancer, consisting of etoposide, doxorubicin and cisplatin, followed by radiotherapy with concomitant cisplatin: A feasibility study

“…The sub-analysis showed a prognostic role of ERCC1 expression. Patients with ERCC1-positive tumors had significantly longer median DFS and OS, and intensified adjuvant chemotherapy may be justified for those patients (14). In the recent presentation of results from the CLASSIC trial (15), a marked improvement in DFS (primary endpoint) and a trend to OS improvement was demonstrated in a group of Asian patients who received an adjuvant XELOX protocol, compared to observation alone.…”

“…The option of administering adjuvant chemotherapy only was renewed recently with promising results from a small, randomized, phase III trial (14) supporting the use of adjuvant platinum/docetaxel chemotherapy instead of chemoradiotherapy. That trial found no differences between the groups, but was underpowered to exclude a beneficial effect of radiotherapy.…”